Free Trial

Cingulate (CING) Competitors

Cingulate logo
$5.50 +0.13 (+2.42%)
Closing price 04:00 PM Eastern
Extended Trading
$5.60 +0.09 (+1.73%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CING vs. CNTB, OTLK, VRCA, ADAP, MIST, SRZN, PYXS, ANRO, JMAC, and BMEA

Should you be buying Cingulate stock or one of its competitors? The main competitors of Cingulate include Connect Biopharma (CNTB), Oncobiologics (OTLK), Verrica Pharmaceuticals (VRCA), Adaptimmune Therapeutics (ADAP), Milestone Pharmaceuticals (MIST), Surrozen (SRZN), Pyxis Oncology (PYXS), Alto Neuroscience (ANRO), Maxpro Capital Acquisition (JMAC), and Biomea Fusion (BMEA). These companies are all part of the "pharmaceutical products" industry.

Cingulate vs. Its Competitors

Cingulate (NASDAQ:CING) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.

Cingulate has higher earnings, but lower revenue than Connect Biopharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CingulateN/AN/A-$15.55M-$8.48-0.65
Connect Biopharma$26.03M4.74-$15.63MN/AN/A

In the previous week, Connect Biopharma had 9 more articles in the media than Cingulate. MarketBeat recorded 11 mentions for Connect Biopharma and 2 mentions for Cingulate. Cingulate's average media sentiment score of 1.87 beat Connect Biopharma's score of 0.68 indicating that Cingulate is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cingulate
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Connect Biopharma
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Cingulate currently has a consensus price target of $26.00, indicating a potential upside of 372.73%. Connect Biopharma has a consensus price target of $7.00, indicating a potential upside of 215.32%. Given Cingulate's higher possible upside, equities analysts plainly believe Cingulate is more favorable than Connect Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cingulate
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
Connect Biopharma
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.50

Connect Biopharma's return on equity of 0.00% beat Cingulate's return on equity.

Company Net Margins Return on Equity Return on Assets
CingulateN/A -229.78% -142.28%
Connect Biopharma N/A N/A N/A

41.3% of Cingulate shares are held by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are held by institutional investors. 5.3% of Cingulate shares are held by insiders. Comparatively, 22.6% of Connect Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Cingulate has a beta of -0.79, suggesting that its share price is 179% less volatile than the S&P 500. Comparatively, Connect Biopharma has a beta of -0.2, suggesting that its share price is 120% less volatile than the S&P 500.

Summary

Connect Biopharma beats Cingulate on 9 of the 13 factors compared between the two stocks.

Get Cingulate News Delivered to You Automatically

Sign up to receive the latest news and ratings for CING and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CING and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CING vs. The Competition

MetricCingulateMED IndustryMedical SectorNASDAQ Exchange
Market Cap$28.33M$3.04B$5.74B$9.51B
Dividend YieldN/A2.40%4.60%3.99%
P/E Ratio-0.6521.1828.1120.03
Price / SalesN/A339.43461.37103.88
Price / CashN/A43.2336.5559.01
Price / Book2.378.368.655.90
Net Income-$15.55M-$55.19M$3.25B$258.66M
7 Day Performance6.38%5.89%4.20%2.23%
1 Month Performance33.82%17.63%10.82%12.76%
1 Year Performance1,347.37%5.09%34.70%19.36%

Cingulate Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CING
Cingulate
3.2576 of 5 stars
$5.50
+2.4%
$26.00
+372.7%
+1,352.1%$28.33MN/A-0.6520News Coverage
Positive News
CNTB
Connect Biopharma
2.8479 of 5 stars
$1.41
-7.2%
$7.00
+396.5%
+74.1%$78.34M$26.03M0.00110Analyst Upgrade
Analyst Revision
High Trading Volume
OTLK
Oncobiologics
2.258 of 5 stars
$2.32
+12.1%
$9.60
+313.8%
-75.5%$77.88MN/A-2.5520News Coverage
VRCA
Verrica Pharmaceuticals
4.1329 of 5 stars
$0.82
+1.0%
$8.00
+881.6%
-90.2%$75.38M$7.57M-0.6840Positive News
Gap Down
ADAP
Adaptimmune Therapeutics
1.9629 of 5 stars
$0.28
+4.6%
$1.35
+381.0%
-73.0%$74.48M$178.03M-1.04490News Coverage
MIST
Milestone Pharmaceuticals
2.8103 of 5 stars
$1.38
-11.5%
$7.00
+407.2%
+6.1%$73.78M$1M-1.7730High Trading Volume
SRZN
Surrozen
2.7641 of 5 stars
$8.61
-1.1%
$38.50
+347.2%
+5.3%$73.73M$11.64M-0.3480Positive News
PYXS
Pyxis Oncology
2.4157 of 5 stars
$1.19
+2.6%
$9.00
+656.3%
-64.5%$73.72MN/A-0.7560
ANRO
Alto Neuroscience
2.4036 of 5 stars
$2.71
+4.0%
$8.50
+214.2%
-79.4%$73.22MN/A-1.16N/ATrending News
JMAC
Maxpro Capital Acquisition
N/A$5.45
-4.4%
N/A+2,812.2%$73.18MN/A0.002,021Gap Up
BMEA
Biomea Fusion
3.2899 of 5 stars
$1.94
-3.0%
$21.40
+1,003.1%
-66.8%$72.89MN/A-0.5550Upcoming Earnings

Related Companies and Tools


This page (NASDAQ:CING) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners